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Abstract
Background: Canine oral fibrosarcoma (COF) is one of the most common oral tumors in dogs and carries a
guarded prognosis due to a lack of effective systemic therapeutic options. Mastinib and imatinib are two
commonly used tyrosine kinase inhibitors (TKIs) in veterinary oncology but their potential efficacy against COF is
uncharacterized. To begin investigating the rationale for use of these TKIs against COF, the present study tested for
the presence TKI targets PDGFR-α, PDGFR-β, Kit, and VEGFR-2 and examined the in vitro effects on cell viability after
TKI treatment alone or with doxorubicin.
Immunohistochemistry for PDGFR-α, PDGFR-β, Kit, and VEGFR-2 was performed in 6 COF tumor biopsies. Presence
of these same receptors within 2 COF cell lines was probed by reverse transcription-polymerase chain reaction and,
for those with mRNA detected, confirmed via western blot. Effects on cell viability were assessed using an MTS
assay after masitinib or imatinib treatment alone (0-100 μM), or in combination with doxorubicin (0-3000 nM
doxorubicin). Anti-PDGFRB siRNA knockdown was performed and the effect on cell viability quantified.
Results: Expression of the TKI targets evaluated was similar between the 2 COF cell lines and the 6 COF tumor
biopsies: PDGFR-α and PDGFR-β were detected in neoplastic cells from most COF tumor biopsies (5/6 and 6/6,
respectively) and were present in both COF cell lines; KIT and KDR were not detected in any sample. Masitinib and
imatinib IC50 values ranged from 7.9–33.4 μM, depending on the specific TKI and cell line tested. The addition of
doxorubicin resulted in synergistic cytotoxicity with both TKIs. Anti-PDGFRB siRNA transfection reduced PDGFR-β
protein expression by 77 % and 67 % and reduced cell viability by 24 % (p < 0.0001) and 28 % (0 = 0.0003) in the
two cell lines, respectively.
Conclusions: These results provide rationale for further investigation into the use of TKIs, possibly in combination
with doxorubicin, as treatment options for COF.
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Background
Canine oral fibrosarcoma (COF) is one of the three most
common oral neoplasms in dogs [1]. Compared to other
anatomic locations, COF exhibits a biologically aggressive
behavior with recurrence rates following resection of 24–
59 %, metastasis in up to 30 % of cases, and reported
median survival times of 7–24 months [2–9]. The most
recent of these studies included 65 dogs and found signifi-
cant predictors of median survival time to include tumor
location (maxillary location better than mandibular), size
(smaller tumors better), type of surgery (aggressive surgery
better than conservative), histologic margin status, and
grade (low grade better). This study included 14 dogs that
received adjuvant systemic therapy (4 received doxorubi-
cin and 10 received metronomic chemotherapy) but be-
cause of this low sample size and the fact that therapy was
often initiated after relapse of disease, no conclusions
could be drawn regarding the potential efficacy of this
treatment strategy [8]. Currently, the prognosis for this
disease remains guarded due to a lack of effective systemic
therapeutic options to address potential metastasis as well
as local recurrence [1–9].
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The use of receptor tyrosine kinase inhibitors (TKIs)
for targeted therapy in veterinary oncology is increasing
as indicated by the growing number of clinical reports
[10–15]. Although some reports describe use of TKIs
alone, others have reported on observed clinical efficacy
when combined with traditional cytotoxic chemothera-
peutic agents and/or piroxicam [10, 11, 13, 15, 16]. Pro-
posed mechanisms behind combination therapy include
chemosensitization as well as immunomodulatory effects
such as suppression of regulatory T cells and restoration
of T cell-mediated immune responses [16]. Masitinib is
conditionally approved by the United States Food and
Drug Administration and the European Medicines
Agency for use against canine mast cell tumors. Masiti-
nib targets PDGFR-α and -β, Kit, Lyn, and to a lesser de-
gree, the FGFR3 and FAK pathways [16]. Masitinib may
also affect VEGFR-2 levels [14]. Imatinib is another TKI
that targets some of the same kinases as masitinib, in-
cluding PDGFR-α, PDGFR-β, and Kit [16, 17]. Although
not approved by the United States Food and Drug Ad-
ministration for use in veterinary patients, off-label vet-
erinary use of imatinib has been reported with favorable
results in canine and feline cancer patients [18–21].
To our knowledge, there are no reports that have pro-
filed expression of tyrosine kinases in COF, nor the po-
tential for targeting by masitinib or imatinib. The
purpose of this study was to (1) evaluate the expression
of PDGFR-α, PDGFR-β, Kit, and VEGFR-2 in archived
COF biopsies and immortalized cell lines and (2) assess
the effects on cell viability of two TKIs (masitinib and
imatinib), either alone or in combination with doxorubi-
cin, against the cell lines in vitro. The results presented
herein begin to shed light on this strategy as a potential
future therapy for COF.
Results
Archived canine oral fibrosarcoma tumors express
PDGFR-α and –β protein
Immunohistochemistry (IHC) for PDGFR-α, PDGFR-β,
Kit, and VEGFR-2 demonstrated differential expression
of each protein amongst the six archived tumor speci-
mens with good agreement between subjective observer-
derived assessments and semi-quantitative software-
derived results (Table 1). Representative photomicro-
graphs for each of the proteins evaluated are shown in
Fig. 1. A representative software threshold-processed
image of tumor cell immunoreactivity for PDGFR-β is
shown in Fig. 2. Higher percentages represent more im-
munoreactivity (i.e. pixels above the user-defined thresh-
old for IHC stain). Mitotic counts in five of six sarcomas
were low, ranging from 1 to 4 in ten 400x high power
fields. Case 3 had a much higher mitotic count (n = 15).
This tumor also had the largest nuclei, poorest overall
organization, and most intense IHC staining for both
PDGFRs.
Staining for PDGFR-α was detected in the cytoplasm
and nuclei of 75–100 % of neoplastic cells in five of the
six tumor samples, with a relatively uniform staining in-
tensity among samples. In all sections, PDGFR-α stain-
ing was also present in the cytoplasm and nuclei of
endothelial cells including neoplastic endothelial cells of
a canine metastatic hemangiosarcoma control sample.
Similarly, PDGFR-β was detected in the cytoplasm of
60–100 % of neoplastic cells in all six tumor samples.
There was relatively uniform intensity and subcellular
location of immunostaining of neoplastic cells in five of
the biopsy samples with a similar distribution but
weaker staining intensity in the remaining sample. Two
samples also showed cell membrane associated PDGFR-
β staining. PDGFR-β stained the cytoplasm of endothe-
lial cells in all sections including neoplastic endothelial
Table 1 Immunohistochemistry reactivity scores
Protein Dog # % Cells Location Intensity % Area
PDGFR-α 1 75 C, N + 29.4
2 80 C, N + 26.2
3 100 C, N ++ 21.6
4 90 C, N ++ 43.9
5 0 – – 0
6 90 C, N + 11.6
PDGFR-β 1 90 C, M +++ 34.8
2 70 C, M ++ 40.8
3 100 C +++ 38.1
4 60 C +++ 23.8
5 90 C + 19.6
6 80 C ++ 21.8
Kit 1 0 – – 0
2 0 – – 0
3 0 – – 0
4 0 – – 0
5 0 – – 0
6 0 – – 0
VEGFR-2 1 0 – – 0
2 0 – – 0
3 0 – – 0
4 0 – – 0
5 0 – – 0
6 0 – – 0
Subjective scoring of immunoreactivity of 6 archived canine oral fibrosarcoma
cases for VEGFR-2, PDGFR-α, PDGFR-β, and Kit. The estimated percentage of
tumor cells displaying immunoreactivity, the predominant location(s) of
staining (C = cytoplasmic, M =membranous, or N = nuclear), and the subjective
intensity of staining (+, ++, or +++) are displayed along with semi-quantitative
measurement of immunoreactivity using computer image analysis software
and threshold-processed photomicrographs
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cells in the hemangiosarcoma control sample. VEGFR-2
and Kit staining were uniformly negative in neoplastic
cells of all six COF tumor samples. Endothelial cells
around but not within the tumors had cytoplasmic stain-
ing for VEGFR-2, whereas neoplastic cells of a meta-
static hemangiosarcoma did not stain. Most sections had
interstitial mast cells that displayed a largely membrane-
associated staining pattern for Kit. In the mast cell
tumor control sample, most neoplastic cells had cyto-
plasmic, perinuclear, punctate staining for Kit (pattern
2); less than 5 % showed diffuse cytoplasmic staining
(pattern 3) [22].
Fig. 1 Immunohistochemistry of archived canine oral fibrosarcoma tumor biopsies. Representative photomicrographs of an archived canine oral
fibrosarcoma tumor specimen (dog #4) stained with (a) hematoxylin and eosin, b PDGFR-α immunohistochemistry, c PDGFR-β immunohistochemistry,
d Kit immunohistochemistry, e VEGFR-2 immunohistochemistry, and f rabbit negative control; 400×. Immunoreactivity for PDGFR-α (both cytoplasmic
and nuclear locations) and PDGFR-β (predominantly cytoplasmic location) is visible. No staining is seen for VEGFR-2, Kit, or in the rabbit
negative control
Fig. 2 Semi-quantitative assessment of immunoreactivity via image threshold-processing. Representative photomicrograph of PDGFR-β
immunohistochemical staining of an archived canine oral fibrosarcoma tumor specimen (dog #6) before (a) and after (b) threshold-
processing for semi-quantitative assessment of immunoreactivity; 400×. Red pixels are reported as percentage of total image pixels to
provide a semi-quantified measure of immunoreactivity
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Canine oral fibrosarcoma cell lines express PDGFR-α and
–β at both mRNA and protein levels
PDGFRA and PDGFRB mRNA was reverse transcribed
and amplified from exponentially growing MBSa1 and
CoFSA cells by reverse transcription-polymerase chain
reaction (RT-PCR; Fig. 3a). Amplicons were of the pre-
dicted size and sequencing reaction results matching the
published sequence with 100 % homology. Transcripts
for KIT and KDR were not detected (Fig. 3a) despite
using two different canine-specific primer sets.
Western blots showed strong expression of both
PDGFR-α and –β in cell lysates from CoFSA, with
weaker expression in MBSa1 (Fig. 3b). These data coin-
cide with the apparent mRNA signals shown in these
two cell lines (Fig. 3a).
Masitinib or imatinib alone, or in combination with
doxorubicin, inhibit canine oral fibrosarcoma cell viability
Masitinib treated cells displayed decreased viability rela-
tive to the vehicle-treated control at concentrations of
10, 30, and 100 μM for both MBSa1 and CoFSA cell
lines (p < 0.0001; Fig. 4a). The calculated IC50 of masiti-
nib for MBSa1 and CoFSA is 9.1 and 12.0 μM,
respectively. Imatinib treated cells displayed decreased
viability relative to the vehicle-treated control at 30.0
and 100.0 μM for MBSa1 (p < 0.0001) and at 1.0, 3.0,
10.0, 30.0, and 100.0 μM for CoFSA (p < 0.0001; Fig. 4b).
The calculated IC50 of imatinib for MBSa1 and CoFSA
is 33.4 and 7.9 μM, respectively.
The combination of either 1.0 μM masitinib or ima-
tinib with doxorubicin yielded synergistic reductions in
cell viability for both cell lines (Fig. 5). Combination
treatment demonstrated synergism in MBSa1 cells at all
doxorubicin concentrations for masitinib and at 1, 3, 10,
30, and 100 nM doxorubicin concentrations for imatinib
(Fig. 5a). Due to the greater reduction in cell viability
seen with 1.0 μM of either TKI alone in CoFSA cells,
synergism was shown only at the highest doxorubicin
Fig. 3 Receptor tyrosine kinase expression in cell lines. a Reverse
transcriptase-polymerase chain reaction for KDR, KIT, PDGFRA, and
PDGFRB in CoFSA and MBSa1 cell lines demonstrates presence of
transcript for both PDGFRA and PDGFRB at the expected amplicon size
with no evidence of KDR or KIT transcript. The molecular weight ladder
is shown on the left side of the image with the base pairs (bp) listed. b
Western blot of PDGFR-α and PDGFR-β demonstrating protein pres-
ence in both CoFSA and MBSa1 cell lines at the expected molecular
weight of 123 kDa. A lysate from 293 T cells was used as a positive
control (SC-114235, Santa Cruz Biotechnology, Dallas, TX)
Fig. 4 Cell viability after treatment with masitinib or imatinib.
Graphical plot of the effects of a masitinib and b imatinib on viability
of MBSa1 and CoFSA cells. Cell viability was assessed using a MTS assay
of MBSa1 and CoFSA treated with escalating concentrations of
masitinib or imatinib after 72 h of incubation. Masitinib treated cells
displayed decreased viability relative to the vehicle-treated control at
10.0, 30.0, and 100.0 μM for both MBSa1 and CoFSA (p < 0.0001).
Imatinib treated cells displayed decreased viability relative to the
vehicle-treated control at 30.0 and 100.0 μM for MBSa1 (p < 0.0001)
and at 1.0, 3.0, 10.0, 30.0, and 100.0 μM for CoFSA (p < 0.0001). Plotted
values are mean ± standard error of the mean. The calculated IC50 of
masitinib for MBSa1 and CoFSA is 9.1 and 12.0 μM, respectively. The
calculated IC50 of imatinib for MBSa1 and CoFSA is 33.4 and
7.9 μM, respectively
Milovancev et al. BMC Veterinary Research  (2016) 12:85 Page 4 of 13
concentrations tested: 10, 300, 1000, and 3000 nM for
masitinib and 300, 1000, and 3000 nM for imatinib
(Fig. 5b).
PDGFRB siRNA knocks down PDGFR-β protein expression
and reduces oral fibrosarcoma cell line viability
Western blot analysis demonstrated that PDGFR-β is
expressed in both MBSa1 and CoFSA cell lines, with a
marked reduction in PDGFR-β expression evident in both
cell lines after PDGFRB siRNA transfection (Fig. 6). Densi-
tometry measurements of actin-normalized PDGFR-β band
intensity (expressed as a percentage of the vehicle-only
treated control cells) revealed a reduction of PDGFR-β
protein in MBSa1 and CoFSA cells of 77.4 % and 67.4 %,
respectively.
Cell viability after PDGFRB siRNA transfection was
significantly reduced in both MBSa1 (mean reduction of
24.0 %; p < 0.0001) and CoFSA (mean reduction of
27.6 %; p = 0.0003) cell lines compared to vehicle-treated
control cells (Fig. 7). Visual comparison of siRNA-
transfected cells to control cells revealed a greater nega-
tive effect on cell viability than was reflected by the
MTS assay results (Fig. 7).
Effect of masitinib and imatinib, alone or combined with
doxorubicin, on oral fibrosarcoma cell line caspase
activity
MBSa1 cells did not demonstrate significant changes in
caspase-3/7 activity at any drug concentration tested (Fig. 8a
and c). In contrast, CoFSA cells did display significantly in-
creased caspase activity at 1.0 μM masitinib alone (Fig. 8b)
and at 300 nM doxorubicin combined with either 1.0 μM
masitinib or imatinib (Fig. 8d); CoFSA cells showed signifi-
cantly reduced caspase activity following treatment with
30 μMmasitinib alone (Fig. 8b).
Discussion
This study begins to explore the potential rationale for
using two commonly prescribed TKIs (masitinib and
imatinib) as adjunctive treatment in COF. The stimulus
Fig. 5 Cell viability following doxorubicin treatment alone or combined
with 1.0 μM of either masitinib or imatinib. Graphical plot of the effects
of treatment with escalating concentrations of doxorubicin alone or
combined with 1.0 μM of either masitinib or imatinib on viability of (a)
MBSa1 and (b) CoFSA cells. Cell viability was assessed using a MTS assay
following treatment with the above drug concentrations after 72 h of
incubation. Masitinib showed a synergistic interaction with doxorubicin
at all concentrations for MBSa1 and at 10, 300, 1000, and 3000 nM for
CoFSA. Imatinib showed a synergistic interaction with doxorubicin at 1,
3, 10, 30, and 100 nM for MBSa1 and at 300, 1000, and 3000 nM for
CoFSA. Plotted values are mean ± standard error of the mean. Synergism
was defined as being present when the surviving fraction of cells
exposed to the combination of doxorubicin and either tyrosine kinase
inhibitor was lower than the product of the surviving fraction of cells
exposed to the tyrosine kinase inhibitor alone multiplied by the surviving
fraction of cells exposed to doxorubicin alone. See Materials and
Methods section for detailed synergism calculation methods
Fig. 6 PDGFR-β reduction following PDGFRB siRNA transfection. Effect
of PDGFRB siRNA transfection on PDGFR-β expression in CoFSA and
MBSa1 cells assessed via western blot. Reduced PDGFR-β levels are
represented as decreased band intensity in the PDGFRB siRNA treated
lanes for both cell lines. Cells were incubated with siRNA for 48 h, as
described in methods. Scrambled siRNA sequence used to account for
nonspecific, off-target effects. To account for differences in protein
loading between lanes, final PDGFR-β knockdown was reported as
percentage of actin-normalized PDGFR-β band intensity in the siRNA
treated lane relative to actin-normalized PDGFR-β band intensity in the
control (vehicle-treated) lane using computer image analysis software
with a gel analysis package (ImageJ v1.47, NIH, Bethesda, MD)
Milovancev et al. BMC Veterinary Research  (2016) 12:85 Page 5 of 13
for this investigation is based on the premise that tar-
geted small molecule therapy may provide an adjuvant
therapeutic strategy for control of COF following sur-
gery, given the challenge of obtaining complete surgical
tumor excision and the reluctance of many pet owners
to pursue adjuvant radiotherapy. We began by testing
for the presence of targets of these two TKIs, including
PDGFR-α, PDGFR-β, VEGFR-2, and Kit, in six archived
COF tumors and two immortalized COF cell lines. Our
results demonstrate a similar expression profile between
the immortalized cell lines and the archived tumor sam-
ples, leading into the second aim of the study: assessing
the effects of the two TKIs on cell viability, either alone
or in combination with doxorubicin. Our data show
both cell lines were relatively resistant to single-agent
TKI treatment, with substantial reductions in cell viabil-
ity and an increase in apoptotic activity being seen only
at relatively high concentrations in most experiments.
Both TKIs met the criteria for synergistic in vitro cyto-
toxicity when combined with doxorubicin, although the
magnitude of this effect was relatively small. Cumula-
tively, the present study provides insight into the poten-
tial validity of future in vivo investigations exploring the
use of TKIs, possibly in combination with traditional
cytotoxic chemotherapeutic agents, as adjuvant treat-
ment options in COF.
Of the four potential TKI targets evaluated via IHC,
PDGFR-β was the most consistently expressed (6/6 of ar-
chived tumors) and showed the strongest immunoreactivity
across tumor samples. Furthermore, PDGFR-β was de-
tected within both cell lines at the mRNA and protein
levels. PDGFR-α was also frequently detected with 5/6 ar-
chived tumor samples showing immunoreactivity, but with
lower subjective staining intensity and scoring lower on our
semi-quantitative immunoreactivity measurements. Both
cell lines also expressed PDGFR-α at both mRNA and pro-
tein levels. The COF tumor sample with the highest mitotic
count and least degree of differentiation was among the tu-
mors with the most intense IHC staining for PDGFR-β and
PDGFR- α, consistent with the positive effect of PDGF on
cell proliferation. Neither Kit nor VEGFR-2 were detected
at the protein level within tumor samples or at mRNA
levels within the cell lines. These data indicate that at least
two targets of the TKIs used in this study are present within
COF tumors and provided a rationale for proceeding with
the evaluation of cell viability following TKI treatment.
The in vitro effect of the tested TKIs on CoFSA and
MBSa1 cell viability was observed to be relatively similar
between the two drugs. These observations are consistent
with the shared targets between the two TKIs [15, 16].
MBSa1 cells were consistently resistant to either TKI, with
significant cytotoxic effects seen only at high concentrations
and no significant changes in apoptosis elicited by any drug
concentration tested. By comparison, CoFSA cells were
similarly resistant to masitinib but slightly more sensitive to
imatinib, with a modest but statistically significant reduc-
tion in cell viability at ≥ 1 μM concentrations. CoFSA cells
also demonstrated significant increases in apoptosis at
Fig. 7 Cell viability following PDGFRB siRNA transfection. Effect of PDGFRB siRNA transfection on (a) CoFSA and (b) MBSa1 cell viability assessed
via an MTS assay after 72 h of incubation, with representative photomicrographs of cells under each condition (CoFSA cells treated with (c)
vehicle alone, d scrambled siRNA sequence, and e PDGFRB siRNA; MBSa1 cells f treated with vehicle alone, g scrambled siRNA sequence, and h
PDGFRB siRNA). Scrambled siRNA sequence used to account for nonspecific, off-target effects. “*” indicates statistically significant (p < 0.05)
differences in cell viability compared to vehicle-treated controls. Because siRNA transfection was performed during two independent experiments,
statistical analysis for these data was performed using the 6 replicates within one representative siRNA experiment. Visual assessment of cellular
appearance in PDGFRB siRNA treated samples (e and h) display apoptotic bodies and marked cellular morphologic deterioration
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select drug concentrations, consistent with their increased
sensitivity to the treatments evaluated in this study. CoFSA
cells also showed a significant decrease in relative caspase
activity at 30 μM masitinib, which may reflect a paucity of
cells with caspase activity due to the extremely low cell via-
bility at this TKI concentration, as supported by our MTS
assay results. These relatively minor differences in TKI sen-
sitivity between cell lines may reflect a combination of dif-
ferences in drug targets between the two TKIs tested along
with differences in the cell lines used [14, 16]. To the au-
thors’ knowledge, no studies have characterized specific re-
ceptor tyrosine kinase pathway dependence in either
MBSa1 or CoFSA cell lines. Several other in vitro veterinary
studies have reported similarly high masitinib or imatinib
IC50 concentrations in canine hemangiosarcoma and feline
injection site sarcoma cell lines [12, 14, 23]. In contrast, the
cell-based IC50s for masitinib against PDGFR-α, PDGFR-β,
and Kit have been reported as 0.3, 0.05, and 0.15 μM, re-
spectively, in an IL3-dependent hematopoietic cell line [24].
These values are markedly lower than the IC50 values seen
in the present and prior in vitro veterinary studies, raising
the possibility that the observed reductions in cell viability
may be due to off-target effects. This is also compatible
with the calculated IC50 values from another veterinary
study evaluating in vitro masitinib effects on a variety of
immortalized canine cancer cell lines [25]. The reason for
this relative resistance to single-agent TKI treatment in the
cell lines in the present report, as well as in the those cell
lines used in the referenced studies, is not fully understood
but likely reflects the cell lines’ lack of dependence on the
targeted pathways for survival [12, 14, 23, 25]. However, as
pointed out in previous reports, findings such as described
in the current study do not preclude a potential clinical
benefit of masitinib therapy either as a single agent target-
ing tumor-related angiogenesis, or perhaps more import-
antly, as a potential chemosensitizer [25].
To begin to investigate the potential role of either
masitinib or imatinib as chemosensitizers in COF, we
performed MTS assays using a range of doxorubicin
concentrations, with or without 1.0 μM of either TKI.
This concentration of TKI was chosen because pharma-
cokinetic studies in healthy Beagle dogs have shown that
a clinically-relevant oral dose of 10 mg/kg of masitinib
results in a serum maximum concentration of 1.3–
1.5 μM [26]. Our data support an in vitro synergistic ef-
fect of either TKI with doxorubicin in both cell lines,
Fig. 8 Cell apoptosis following treatment with imatinib and masitinib, alone or combined with doxorubicin. Graphical plot of relative caspase
activity following treatment with escalating concentrations of masitinib and imatinib alone (a and b) and doxorubicin combined with 1.0 μM of
either masitinib or imatinib (c and d) on MBSa1 and CoFSA cells, respectively. Caspase activity was assessed using a luminogenic caspase-3/7
substrate assay following treatment with the above drug concentrations after 72 h of incubation and expressed as a percentage of caspase
activity within vehicle-treated (DMSO 0.1 %) control cells. COS cells treated with SB2224269 represent a positive control. Plotted values are mean
± standard error of the mean. “*” indicates statistically significant (p < 0.001) difference compared to the vehicle-treated controls indicated by a
one-way ANOVA with Dunnett’s correction
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although the effect was modest. The potential for myelo-
suppression, or other side-effects, may be increased
when TKIs are combined with traditional cytotoxic che-
motherapeutic agents in vivo, as shown in a study evalu-
ating the safety of toceranib combined with vinblastine
in dogs with mast cell tumors [16]. Maximal
sensitization factors, potential alterations in drug
pharmacokinetics, and alternative methods for determin-
ing pharmacologic synergism were not considered as
they extend beyond the scope of the present study, but
may form the basis for future investigations.
As PDGFR-β was found to be the most uniformly
expressed receptor tyrosine kinase for TKI targeting in
the present study, we chose to further investigate the
contribution of PDGFR-β signaling to viability of COF
cell lines. Knockdown of PDGFR-β protein expression
via siRNA transfection was successful in both cell lines.
The effect of this PDGFR-β protein reduction was asso-
ciated with a significant reduction in cell viability in both
cell lines as well as visibly apparent degenerative changes
in cellular morphology. This suggests that PDGFR-β sig-
naling plays a partial role in maintaining viability of
COF cells, but the overall significance of this single sig-
naling pathway to COF cell survival requires further
investigation.
Although a thorough discussion of the mechanism of
action of imatinib and masitinib is beyond the scope of
this report, a few select points are worth highlighting.
Both TKIs are considered small molecule inhibitors that
selectively interfere with specific receptor tyrosine kinase
activity (PDGFR-α, -β, and Kit; masitinib also targets
Lyn, the FGFR3 and FAK pathways and possibly
VEGFR-2 levels) [14, 16, 27]. Through occupying the re-
ceptor’s active site, thereby blocking receptor tyrosine
kinase phosphorylation, TKIs prevent subsequent activa-
tion of downstream pathways. Depending on the cell’s
dependence on the targeted pathways, this may result in
cell death [16]. Some TKIs, such as masitinib, have
shown an anticancer action that extends beyond inhib-
ition of its primary targets, and may include disruption
of additional signaling pathways associated with tumor
progression, metastasis, and chemoresistance [25, 26, 28,
29]. The in vivo tumor microenvironment is character-
ized by varying levels of hypoxia and acidity, which in-
fluence tumor cell behavior and drug sensitivity,
potentially rendering them more or less sensitive to TKI
treatment [30]. PDGFR is emerging as a key regulator of
mesenchymal cells within the tumor microenvironment
of many common human malignancies [31]. Blockade of
PDGFR signaling has been shown to reduce metastasis
in in vivo murine models of colorectal and prostate can-
cers [32–34]. These points serve to illustrate some of the
impetus behind this study’s investigations into the use of
TKIs as a potential treatment strategy, although their
applicability to imatinib and/or masitinib treatment of
COF remain unknown at this time.
The primary limitations of the present study center on
its in vitro nature and the limited experimental methods
used. This study tested for receptor tyrosine kinase ex-
pression but did not evaluate receptor phosphorylation
status (i.e. activation), receptor over- or under-
expression, or effect of ligand stimulation on the recep-
tors present. The presence of TKI targets does not ne-
cessarily imply their requirement for cell survival or a
gain-of-function structural aberration conferring malig-
nant behavior. This study evaluated effects of TKI treat-
ment on COF cell line viability using an MTS assay,
supplemented with an apoptosis assay for select drug
concentrations, representing only a partial evaluation of
potential TKI effects. Examples of additional treatment
effects that could be examined in future studies include
COF cell migration and/or metastasis. Finally, it is diffi-
cult to extrapolate in vitro results of TKI treatment to
the far more complex in vivo scenario that includes in-
teractions with the tumor microenvironment and the
host immune system.
Conclusions
In conclusion, this study identified expression of
PDGFR-α and –β in COF tumor biopsies and cell lines.
Treatment with masitinib or imatinib yielded in vitro re-
ductions in cell viability which was enhanced synergistic-
ally by the addition of doxorubicin. Furthermore, the
tested COF cell lines exhibited partial PDGFR-β depend-
ency for survival. Taken together, these data support fur-
ther investigation into the potential use of TKIs,
potentially in combination with doxorubicin, to augment
existing treatment options for COF.
Methods
Immunohistochemistry of archived canine oral
fibrosarcomas
Medical records from dogs seen at the Oregon State
University Lois Bates Acheson Veterinary Teaching Hos-
pital between 2007 and 2011 were searched to identify
histologically confirmed COF tumor biopsies. All tumors
were comprised of elongate to spindle cells arranged in
streams or bundles and whorls that produced variable
amounts of collagenous matrix. Four of the tumors had
small heterochromatic nuclei, case 1 had medium-sized
and case 3 had large euchromatic nuclei. The diagnosis
of COF was confirmed by examination of a representa-
tive hematoxylin and eosin stained section from each bi-
opsy by a single board-certified veterinary anatomic
pathologist (CVL). Serial sections 4–5 μm thick from
paraffin-embedded formalin-fixed tumor biopsies were
mounted on positively charged slides for IHC analysis of
PDGFR-α, PDGFR-β, Kit, and VEGFR-2 expression
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using anti-human receptor-specific polyclonal rabbit
antibodies (detailed in Table 2) [35–37].
High temperature antigen retrieval was performed
with a microwave pressure cooker using Dako Target
Retrieval solution (pH 6, 10 mins) according to the man-
ufacturer’s recommendationsa. IHC staining was per-
formed on a Dako Autostainer (Dako North America,
Carpinteria, CA) at room temperature (21 °C) after
blocking for 10 mins with 3 % H2O2 (Sigma Laborator-
ies, Santa Fe, NM) in TBST (Biocare Medical, Concord,
CA) followed by Dako serum-free protein block (Dako
North America, Carpinteria, CA) for 10 mins. The pri-
mary antibodies were diluted in Dako antibody diluent
(Dako North America, Carpinteria, CA) and applied for
30 mins. Conditions and manufacturer information are
detailed in Table 2. Specific antibody binding was de-
tected using MaxPoly-One polymer HRP rabbit (Immu-
noBioScienceIH-8064-custom-OrSU, Immuno-
BioScience, Mukilteo, WA) for 10 mins followed by
Nova Red (SK-4800, Vector Laboratories, Burlingame,
CA) for 5 mins. Hematoxylin (Dako North America,
Carpinteria, CA) diluted 1:3 in distilled water for 5 mins
was used as a counter stain. Washes between steps were
performed using TBST (Biocare Medical, Concord, CA),
except no wash was performed for the protein block.
Dako Universal Negative Control-Rabbit (Dako North
America, Carpinteria, CA) was used as the negative con-
trol. Peritumoral non-neoplastic tissues were used as in-
ternal positive (endothelium or mast cells) and negative
(epidermis) controls, a canine cutaneous mast cell tumor
submitted as biopsy served as positive control for Kit
staining, and a canine metastatic hemangiosarcoma
(liver, kidney, testis, spleen) collected during necropsy
was used as a positive control [37–39]. Evaluation of
IHC staining for specificity was performed by a board-
certified veterinary anatomic pathologist (CVL).
Immunohistochemistry scoring
Immunoreactivity for PDGFR-α, PDGFR-β, Kit, and
VEGFR-2 were scored by three of the investigators
(CVL, MM, and SB) with the results representing a con-
sensus agreement between the observers. The criteria
evaluated included: percentage of tumor cells displaying
immunoreactivity (assessed from a representative 40×
field, after examining the slide in its entirety), the
predominant location of staining (cytoplasmic, mem-
branous, or nuclear), and relative visual intensity of
staining (+, ++, or +++).
In addition, semi-quantitative measurement of immu-
noreactivity for the same proteins (using a photomicro-
graph of the same IHC field as described above) was
carried out using a computer image analysis software
package (ImageJ v1.47, NIH, Bethesda, MD) as previ-
ously described [40]. Output data recorded was the per-
centage of image pixels above the user-defined threshold
to capture immunoreactivity.
Cell lines and reagents
Two immortalized COF cell lines were tested: MBSa1
(provided by Dr. Marlene Hauck, North Carolina State
University, Raleigh, NC, USA) and CoFSA (provided by
Dr. Melanie Wergin, University of Zurich, Zurich,
Switzerland). Both cell lines were derived from biopsies
acquired from clinically affected dogs presented for
spontaneously arising COF [41, 42]. Cells were cultured
in RPMI-1640 medium supplemented with 10 % fetal
bovine serum, 2 mM glutamine, 2 mM sodium pyruvate,
2 mM HEPES, and 1 % pen-strep in a humidified 5 %
CO2 atmosphere at 37 °C.
Masitinib powder (provided by AB Science, Paris,
France) was suspended in DMSO and stored at -80 °C
until use. Imatinib was purchased from a commercial
supplier (LC Labs, Woburn, MA), suspended in DMSO
and stored at -80 °C until use. Doxorubicin HCl (2 mg/
ml) in isotonic solution was purchased from a commer-
cial supplier (Amneal-Agila, Glasgow, KY). Dimethyl
sulofoxide concentrations in all experiments never
exceeded 0.3 %.
Reverse transcription-polymerase chain reaction
Expression of transcripts for PDGFRA, PDGFRB, KIT,
and KDR was assessed in MBSa1 and CoFSA cells using
RT-PCR. Cells were seeded into six-well plates (3 × 105/
well) suspended in 2.0 mL supplemented medium and
allowed to adhere overnight. The cells were rinsed in
PBS and RNA was isolated (RNeasy, Qiagen, Valencia,
CA) and reverse transcribed to cDNA (High Capacity
Reverse Transcription, Applied Biosystems, Foster City,
CA) according to the manufacturers’ instructions. Tar-
gets were amplified from cDNA using the specific
Table 2 Antibodies and conditions used for immunohistochemical staining of archived canine oral fibrosarcoma tumor specimens
Target Manufacturer Antibody Dilution Species HTAR
VEGFR-2 Novus Biologicals, Littleton, CO NBP1-74001 1:100 Rabbit +
PDGFR-α Santa Cruz Biotechnology, Dallas, TX SC-338 1:200 Rabbit +
PDGFR-β BioGenex Laboratories, San Ramon, CA N463-UC 1:200 Rabbit +
Kit Dako North America, Carpinteria, CA A4502 1:500 Rabbit +
HTAR High temperature antigen retrieval at pH 6
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primers (Invitrogen, Carlsbad, CA) listed in Table 3 with
the following accession numbers: [PDGFRA GenBank:
XM532374.5; PDGFRB GenBank: NM001003382.1; KIT
GenBank: XM005627969.2; and KDR GenBank:
NM001048024.1]. Reverse transcription-polymerase
chain reaction was performed according to standard
methods [43] using Taq DNA polymerase (Invitrogen,
Carlsbad, CA), with an annealing temperature of 58 °C,
melting temperature of 94 °C, and run for 34 cycles on a
thermocycler (Bio-rad Laboratories, Hercules, CA).
Products were separated by agarose gel electrophoresis
and visualized under ultra-violet light with propidium
iodide and recorded using an Image Quant LAS4000
digital image capture system (GE Healthcare, Pittsburg,
PA). Amplicons were purified using magnetic beads
(Invitrogen, Carlsbad, CA) and sequenced on an ABI
Prism 3730 Genetic Analyzer (Applied Biosystems,
Grand Island, NY) using the Sanger method (BigDye
Terminator v. 3.1 Cycle Sequencing Kit, Life Technolo-
gies, Grand Island, NY). Results reported are representa-
tive of three independent experiments, with each cell
line tested in triplicate during each experiment.
Western blot
Western blots were performed against proteins for
which mRNA transcripts were detected via RT-PCR in
MBSa1 and CoFSA cells. Cells were seeded in 6-well
plates (3 × 106/well) and allowed to adhere overnight as
described above. The cells were detached using a cell
scraper, transferred to a micro-centrifuge tube, and cen-
trifuged in a tabletop centrifuge (3 min, 1200 × g). Cell
pellets were rinsed by re-suspending twice in 3 mL ice
cold PBS and extracted in 50 μL ice cold RIPA buffer
with protease and phosphatase inhibitor cocktail (Sigma
Laboratories, Santa Fe, NM). Extracts were sonicated
four times (1 s each) using a Model 150 T ultrasonic dis-
membrator (Fisher Scientific, Pittsburg, PA) and pelleted
at 10,000 × g to remove cellular debris. Protein concen-
tration was measured using a Bradford assay (Bio-rad
Laboratories, Hercules, CA) according to the manufac-
turer’s instructions. Proteins (20 μg/lane) were separated
on 4–12 % SDS polyacrylamide gels (Bio-rad Laborator-
ies, Hercules, CA) and transferred to PVDF membranes.
The membranes were blocked in 1.5 % bovine serum al-
bumin and probed with either anti-PDGFR-β antibody
(BioGenex, Fremont, CA) or anti-PDGFR-α antibody
(antibody #SC-388, Santa Cruz Biotechnology, Dallas,
TX) diluted 1:1000 and incubated overnight at 4 °C. The
membranes were washed, probed with horseradish
peroxidase-linked secondary antibody (SC-2005, Santa
Cruz Biotechnology, Dallas, TX) diluted 1:20000, and ex-
posed to substrate (ECL Select, GE Healthcare, Pitts-
burg, PA). A lysate from 293 T cells was used as a
positive control (SC-114235, Santa Cruz Biotechnology,
Dallas, TX). Bands were visualized and recorded using
an Image Quant LAS4000 digital image capture system.
Western blot results reported are representative of two
independent experiments.
Cell viability assay
An MTS colorimetric assay (CellTiter 96 Aqueous One
Solution Cell Proliferation Assay, Promega, Madison,
WI) was used according to the manufacturer’s instruc-
tions to assess the effects of masitinib and imatinib on
viability of COF cell lines. Briefly, growing cells were
seeded into 96-well plates at 2,500 cells/well suspended
in 100 μL of supplemented medium and incubated over-
night prior to adding drugs to allow adherence. Frozen
aliquots of each TKI were thawed and diluted to twice
the desired concentrations in supplemented medium
prior to adding 100 μL to wells containing cells. The
final TKI concentrations included the following: 0, 0.1,
0.3, 1.0, 3.0, 10.0, 30.0, and 100.0 μM. Cultures were
maintained for 72 h following addition of the drugs,
after which 150 μL of the media was removed and re-
placed with 20 μL MTS reagent premixed with 50 μL
supplemented media. Cells were incubated in the
presence of the MTS reagent for 2–4 h. Two cell-
free, media-only wells were included in each experi-
ment to generate assay background values, which
were subtracted from the absorbance of each well
prior to calculating viability indices. Results from TKI
treated cells were compared against controls com-
prised of cells cultured under identical conditions
with 0.3 % DMSO, but without added TKI. There
was no difference in viability between cell lines
treated with DMSO only (data not shown).
To assess the potential for a chemosensitizing effect of
the tested TKIs with doxorubicin, MTS cell viability ex-
periments were performed as described above with doxo-
rubicin either alone or combined with 1.0 μM of either
masitinib or imatinib. This concentration of TKI was
Table 3 Primers used for reverse transcriptase-polymerase chain reaction of immortalized canine oral fibrosarcoma cell lines
Target Forward primer sequence (5′-3′) Reverse primer sequence (5′-3′) Spanned mRNA sequence Product size (bp)
PDGFRA CCTCGATCCTTCCAAATGAA GGTCACAAAAAGGCCACTGT 357-523 167
PDGFRB GTGGTATGGGAACGGTTGTC GTGGGATCTGGCACAAAGAT 228-421 194
KIT CCCATTTAACCGAACGAGAA TCTCCGTGATCTTCCTGCTT 2016-2226 211
KDR GATCGGTGAGAAATCCCTGA CTGGAAGTCATCCACGTTT 1266-1473 208
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chosen because pharmacokinetic studies in healthy Beagle
dogs show that a clinically-relevant oral dose of 10 mg/kg
of masitinib results in a serum maximum concentration of
1.3–1.5 μM [26]. Doxoribucin concentrations tested in-
cluded 0, 1, 3, 10, 30, 100, 300, 1000, and 3000 nM. Re-
sults from drug-treated cells were compared to controls of
cells cultured under identical conditions with 0.3 %
DMSO and without added doxorubicin or TKI.
Three MTS experiments were performed independ-
ently and each condition was run in triplicate within
each experiment.
The type of interaction between each TKI and doxo-
rubicin was determined using the following equations
[44]:
Synergistic ¼ SFtþy < SFtx SFy
Additive ¼ SFtþy ¼ SFtx SFy
Sub‐additive ¼ SFtx SFy < SFtþy < SFtand SFy
Antagonistic ¼ SFtþy > SFtor SFy
SFt+y = surviving fraction of cells exposed to the com-
bination of either TKI and doxorubicin, SFt = surviving
fraction of cells exposed to either TKI alone, SFy = sur-
viving fraction of cells exposed to doxorubicin alone.
These equations are appropriate provided the drug effect
is reduced cell viability [45], a condition that was met at
all drug concentrations except at 3 and 10 nM doxorubi-
cin in CoFSA where the mean cell viability values for
doxorubicin treatment alone were slightly increased. In
these exceptions, the SF of the control group (i.e. cells,
but no doxorubicin or TKI) was substituted in the equa-
tion for the SF of doxorubicin, as it was the more strin-
gent condition for evaluating drug interaction.
All MTS testing was performed during three inde-
pendent experiments, with each condition run in tripli-
cate during each experiment.
Inhibition of PDGFR-β expression by siRNA
PDGFR-β knockdown was used to assess the role of
PDGFR-β in sustaining viability of COF cell lines MBSa1
and CoFSA. Cells were seeded into 96-well plates (5 ×
103 cells/well) and allowed to adhere overnight before
transfection with a combination of four commercially
purchased target-specific siRNAs (Life Technologies,
Carlsbad, CA; 3 pmol per reaction) against canine
PDGFRB (Dharmacon, Lafayette, CO) or a scrambled se-
quence (Mission siRNA Universal Negative Control #1,
Sigma Laboratories, Santa Fe, NM) using Lipofectamine
RNAiMAX (Invitrogen, Carlsbad, CA) according to the
manufacturer’s directions. Cell viability was measured in
96-well plate format 72 h after siRNA transfection using
the MTS colorimetric assay (CellTiter 96 Aqueous One
Solution Cell Proliferation Assay, Promega, Madison,
WI) as described above.





All siRNA data were normalized to the readouts taken
from control cells treated with the transfection reagent
alone, and included scrambled sequence controls to as-
sess for nonspecific, off-target effects. Results from
siRNA knockdown reported are representative of two in-
dependent experiments, with each condition run in sex-
tuplicate during each experiment.
Western blot was repeated after siRNA treatment, as
described above, using only the anti-PDGFR-β antibo-
dy(BioGenex, Fremont, CA). Quantification of siRNA
PDGFR-β protein knockdown was performed using
computer image analysis software with a gel analysis
package (ImageJ v1.47, NIH, Bethesda, MD). PDGFR-β
signal intensities in each lane were expressed as percent-
age of the total protein control (actin) loaded into re-
spective lanes. Final PDGFR-β protein knockdown was
reported as percentage of actin-normalized PDGFR-β
band intensity in the siRNA treated lane relative to
actin-normalized PDGFR-β band intensity in the control
(vehicle-treated) lane.
Apoptosis
A luminogenic caspase-3/7 substrate assay (Caspase-Glo
3/7, Promega, Madison, WI) was used to determine rela-
tive caspase activity in COF cell lines after TKI treatment,
either alone or with doxorubicin. The drug concentrations
tested were selected based on MTS results in order to rep-
resent the range of observed effects on cell viability. Cells
were seeded in 96-well culture plates at a density of 2,500
cells/well and challenged with the following drugs (con-
centrations): masitinib (0, 1, 3, and 30 μM), imatinib (0, 1,
3, and 30 μM), masitinib 1.0 μM+doxorubicin (3 and 300
nM), and imatinib 1.0 μM+doxorubicin (3 and 300 nM).
For an apoptosis positive control, COS cells were incu-
bated with 6.25 μM SB2224289 (Tocris, Bristol, UK) [46].
For a vehicle control, cells were incubated with 0.1 %
DMSO in media. Drugs were dissolved in DMSO, with
cells exposed to a final vehicle concentration of 0.1 %.
Cells were challenged for 72 h, after which the caspase-3/
7 activity was quantified. The caspase activity assay was
performed according to the manufacturer’s protocol. Cu-
mulative luminescence over 1 s was measured using a
luminometer (GloMax 96 Microplate Luminometer, Pro-
mega, Madison, WI). Relative caspase activity was calcu-
lated using the formula: relative caspase activity = (mean
luminescence of treated cells)/(mean luminescence of ve-
hicle control) × 100.
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As this experiment was intended to act as a supple-
ment to the MTS assay observations, only a single inde-
pendent experiment (with each drug treatment
condition in triplicate) was performed.
Statistical analysis
Mean cell viability (as described above) was compared to
vehicle-treated control cells using a one-way ANOVA
with Dunnett’s multiple comparisons post-test. Except
for siRNA experiments, all statistical analyses were per-
formed using means from each independent experiment
with standard deviations representing differences be-
tween the means. Because siRNA transfection was per-
formed during two independent experiments, statistical
analysis for these data were performed using the 6 repli-
cates within one representative siRNA experiment. The
50 % inhibitor concentration (IC50) of masitinib and
imatinib for CoFSA and MBSa1 were calculated using
non-linear regression of the log of the inhibitor versus a
variable slope response equation, with constraints set at
100 % for the top and 0 % for baseline. Relative caspase
activities within the various drug treatment conditions
were compared to vehicle-treated control cells with a
one-way ANOVA with Dunnett’s correction using the
technical replicate data from the apoptosis experiment.
Significance was set at p < 0.05 and all statistical testing
was performed using a commercially available computer
software program (Graphpad Prism v6.02 for Windows,
Graphpad Software, San Diego, CA).
Abbreviations
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